Endocrine Today has compiled a list of the top 10 news reports posted so far in of 2019.
Healio.com/Endocrinology readers were interested in diets that improve insulin outcomes, testosterone therapy, results of the CAROLINA cardiovascular outcomes trial, FDA approvals of romosozumab and oral hydrogel therapy for obesity, and more.
Alternate-day fasting cuts insulin levels, resistance in half
Alternate-day fasting lowered levels of fasting insulin and insulin resistance to a greater degree than calorie restriction among adults with overweight or obesity and insulin resistance.
Low-dose hCG can prevent sterility in men prescribed testosterone
Low-dose human chorionic gonadotropin, or hCG, may preserve spermatogenesis in men with hypogonadism treated with intramuscular or transdermal testosterone replacement therapy.
Maternal HbA1c influences autism risk in offspring
Children born to women with an HbA1c of at least 6.5% were nearly twice as likely to receive a diagnosis of autism in the first 4 years of life vs. offspring of mothers with HbA1c below 5.7%.
Insulin patch proves effective for adults with type 2 diabetes
An insulin patch can safely provide similarly effective glycemic management in adults with type 2 diabetes compared with a standard insulin pen.
FDA approves romosozumab for osteoporosis
The FDA approved the monoclonal antibody romosozumab to treat osteoporosis in postmenopausal women at high risk for fracture.
Supplements, cancer therapies, endocrine-disrupting chemicals can alter thyroid function
Medications, supplements, excessive iodine intake and other exogenous substances including endocrine-disrupting chemicals can influence multiple thyroid effects that clinicians should recognize, including thyroid dysfunction and altered thyroxine absorption.
Vitamin D supplementation increases insulin sensitivity, beta-cell function
Taking 5,000 IU of vitamin D per day may improve insulin sensitivity and beta-cell function for those with prediabetes or type 2 diabetes.
CAROLINA: Linagliptin demonstrates CV safety vs. sulfonylurea in type 2 diabetes
Top-line results from the CAROLINA study demonstrated that the DPP-IV inhibitor linagliptin was noninferior vs. glimepiride for time to first major adverse cardiovascular event in adults with type 2 diabetes at high CV risk.
FDA approves hydrogel pill for overweight, obesity
The FDA approved an oral hydrogel therapy that induces feelings of fullness without adding calories for adults with overweight and obesity.
FDA issues complete response letter for sotagliflozin
The FDA issued a complete response letter regarding a new drug application for oral sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor for adult with type 1 diabetes.